These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
708 related articles for article (PubMed ID: 32372515)
21. Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Chan TT; Chan WK; Wong GL; Chan AW; Nik Mustapha NR; Chan SL; Chong CC; Mahadeva S; Shu SS; Lai PB; Chan HL; Wong VW Am J Gastroenterol; 2020 Jun; 115(6):867-875. PubMed ID: 32149781 [TBL] [Abstract][Full Text] [Related]
22. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Estes C; Razavi H; Loomba R; Younossi Z; Sanyal AJ Hepatology; 2018 Jan; 67(1):123-133. PubMed ID: 28802062 [TBL] [Abstract][Full Text] [Related]
23. Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014. Kim D; Cholankeril G; Li AA; Kim W; Tighe SP; Hameed B; Kwo PY; Harrison SA; Younossi ZM; Ahmed A Liver Int; 2019 Sep; 39(9):1661-1671. PubMed ID: 31081997 [TBL] [Abstract][Full Text] [Related]
24. Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S. Younossi ZM; Tampi RP; Racila A; Qiu Y; Burns L; Younossi I; Nader F Diabetes Care; 2020 Feb; 43(2):283-289. PubMed ID: 31658974 [TBL] [Abstract][Full Text] [Related]
25. Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults. Marengo A; Jouness RI; Bugianesi E Clin Liver Dis; 2016 May; 20(2):313-24. PubMed ID: 27063271 [TBL] [Abstract][Full Text] [Related]
26. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease. Lee TY; Wu JC; Yu SH; Lin JT; Wu MS; Wu CY Int J Cancer; 2017 Oct; 141(7):1307-1314. PubMed ID: 28509327 [TBL] [Abstract][Full Text] [Related]
27. Updates in characteristics and survival rates of cirrhosis in a nationwide cohort of real-world U.S. patients, 2003-2021. Tran S; Zou B; Lee K; Kam L; Yeo Y; Henry L; Cheung R; Nguyen MH Aliment Pharmacol Ther; 2024 Jul; 60(2):212-223. PubMed ID: 38693757 [TBL] [Abstract][Full Text] [Related]
28. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013. Beste LA; Leipertz SL; Green PK; Dominitz JA; Ross D; Ioannou GN Gastroenterology; 2015 Nov; 149(6):1471-1482.e5; quiz e17-8. PubMed ID: 26255044 [TBL] [Abstract][Full Text] [Related]
29. Increased risk of cirrhosis and hepatocellular cancer during long-term follow-up of patients with biopsy-proven NAFLD. Önnerhag K; Nilsson PM; Lindgren S Scand J Gastroenterol; 2014 Sep; 49(9):1111-8. PubMed ID: 24990583 [TBL] [Abstract][Full Text] [Related]
30. Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis. Kodama K; Kawaguchi T; Hyogo H; Nakajima T; Ono M; Seike M; Takahashi H; Nozaki Y; Kawanaka M; Tanaka S; Imajo K; Sumida Y; Kamada Y; Fujii H; Seko Y; Takehara T; Itoh Y; Nakajima A; Masaki N; Torimura T; Saibara T; Karino Y; Chayama K; Tokushige K J Gastroenterol Hepatol; 2019 Sep; 34(9):1626-1632. PubMed ID: 30668889 [TBL] [Abstract][Full Text] [Related]
31. Epidemiology of Non-alcoholic Fatty Liver Disease in North America. Arshad T; Golabi P; Henry L; Younossi ZM Curr Pharm Des; 2020; 26(10):993-997. PubMed ID: 32124690 [TBL] [Abstract][Full Text] [Related]
32. Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis. Rich NE; Oji S; Mufti AR; Browning JD; Parikh ND; Odewole M; Mayo H; Singal AG Clin Gastroenterol Hepatol; 2018 Feb; 16(2):198-210.e2. PubMed ID: 28970148 [TBL] [Abstract][Full Text] [Related]
33. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. Streba LA; Vere CC; Rogoveanu I; Streba CT World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859 [TBL] [Abstract][Full Text] [Related]
34. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease. Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516 [TBL] [Abstract][Full Text] [Related]
35. Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain. Romero-Gomez M; Kachru N; Zamorano MA; Darba J; Shreay S Medicine (Baltimore); 2020 Dec; 99(50):e23506. PubMed ID: 33327291 [TBL] [Abstract][Full Text] [Related]
36. Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany. Canbay A; Kachru N; Haas JS; Meise D; Ozbay AB; Sowa JP Ann Transl Med; 2021 Apr; 9(8):615. PubMed ID: 33987313 [TBL] [Abstract][Full Text] [Related]
37. [Advances in diagnosis and treatment of nonalcoholic fatty liver disease]. Zhu C; Zhou D; Fan J Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):81-4. PubMed ID: 26983471 [TBL] [Abstract][Full Text] [Related]
38. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern. Dhamija E; Paul SB; Kedia S Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369 [TBL] [Abstract][Full Text] [Related]
39. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis. Bengtsson B; Stål P; Wahlin S; Björkström NK; Hagström H Liver Int; 2019 Jun; 39(6):1098-1108. PubMed ID: 30829446 [TBL] [Abstract][Full Text] [Related]